http://www.fpnotebook.com/
Anti-psychoticAka: Antipsychotic, Neuroleptic
- Indications
- Psychosis (e.g. Schizophrenia)
- Efficacy: Newer low potency agents
- Atypicals only slightly better than high potency agents
- Similar efficacy in control of Psychosis
- Slightly less Extrapyramidal Side Effects (EPSE)
- Clozapine has much less EPSE, but has diabetes risk
- Higher weight, lipid and diabetes related conditions
- Compliance is similar for both types of agents
- Atypical Antipsychotics are much more expensive
- References
- Barry (2003) Am Fam Physician 68(5):943
- Leucht (2003) Lancet 361:1581
- D2 Antipsychotic Agents: High Potency
- Extrapyramidal Side Effects (EPSE) with all
- Haloperidol (Haldol) or Haloperidol decanoate
- Perphenazine (Trilafon)
- Well tolerated with similar efficacy to other agents
- Lieberman (2005) N Engl J Med 353:1209
- Thiothixene HCl (Navane)
- Typical Dose: 10 mg tid
- Maximum Dose: 60 mg per day
- Fluphenazine HCl (Prolixin)
- Typical Dose: 2.5 mg PO bid
- Maximum Dose: 40 mg PO or 100 mg IM per day
- Trifluoperazine (Stelazine)
- D2 Antipsychotic Agents: Medium Potency
- Loxapine (Loxitane)
- Molindone (Moban)
- D2 Antipsychotic Agents: Low Potency
- Chlorpromazine HCl (Thorazine) - not available in U.S.
- Anticholinergic Symptoms
- Alpha adrenergic blockade (Hypotension)
- Sedation
- Maximum dose: 1000 mg per day
- Thioridazine HCl (Mellaril) - not available in U.S.
- Anticholinergic Symptoms
- Alpha adrenergic blockade (Hypotension)
- Sedation
- Maximum Dose: 800 mg per day
- Atypical Antipsychotics: Serotonin-Dopamine Antagonists
- DiBenzodiazepine (Clozapine, Clozaril)
- Olanzapine (Zyprexa)
- Quetiapine (Seroquel)
- Risperidone (Risperdal)
- Ziprasidone (Geodon)
- Aripiprazole (Abilify)
- Adverse effects
- See Extrapyramidal Side Effects (EPSE)
- Ventricular arrhythmia (including Cardiac arrest)
- Antipsychotic agent relative risk: 3.2
- Drugs studied
- Risperidone (Highest risk)
- Haloperidol (Second highest risk)
- Thioridazine
- Clozapine
- References
- Hennessy (2002) BMJ 325:1070
- Monitoring
- Extrapyramidal Side Effects (EPSE) - all agents
- Screen for Tardive Dyskinesia at each visit
- Screen for other EPSE symptoms
- Educate about Neuroleptic malignant syndrome
- Obesity Monitoring (all Antipsychotics)
- Calculate BMI every 6 months
- Diabetes Mellitus Screening (Newer, atypical agents)
- Baseline fasting Serum Glucose
- Hemoglobin A1C at four months after starting agent
- Screen for polyuria and polydipsia at each visit
- Hyperlipidemia (Newer, atypical agents)
- Baseline lipid profile
- Repeat lipids every 6 months if abnormal
- May decrease frequency to every 2 years if normal
- References
- Marder (2004) Am J Psychiatry 161:1334
- References
- Geddes (2000) BMJ 321:1371
- Glick (2001) Ann Intern Med 134:47
- Lieberman (2005) N Engl J Med 353:1209
Navigation Tree